Mechanism of potentiation of antithrombin III and heparin cofactor II inhibition by sulfated xylans.

Antithrombin-III assay without influence of heparin cofactor II.

Simultaneous determination of plasma prothrombin and antithrombin III (heparin cofactor).

Laboratory diagnosis of antithrombin and heparin cofactor II deficiency.

Inhibition of purified plasma kallikrein by antithrombin III and heparin.

The inhibition of thrombin and chymotrypsin by heparin-cofactor II.

Metabolism of antithrombin III (heparin cofactor) in man: effects of venous thrombosis and of heparin administration.

Heparin cofactor II deficiency in the elderly: comparison with antithrombin III.

Different glycoforms of human thrombomodulin. Their glycosaminoglycan-dependent modulatory effects on thrombin inactivation by heparin cofactor II and antithrombin III.

Antithrombin III and heparin.

Antithrombin III and heparin.

A new two-stage functional assay for antithrombin-III (heparin cofactor): clinical and laboratory evaluation.

Antithrombin-heparin cofactor: an inhibitor of plasma kallikrein.

Effect of heparin modification on its activity in enhancing the inhibition of thrombin by antithrombin III.

Evidence for a plasma inhibitor of the heparin accelerated inhibition of factor Xa by antithrombin III.

Effect of heparin on thrombin inactivation by antithrombin-III.

Interaction of factor Xa with heparin does not contribute to the inhibition of factor Xa by antithrombin III-heparin.

Letter: DIC-fibrinolysis with low antithrombin-heparin cofactor.

Heparin-induced decrease in circulating antithrombin-III.

Immunologic measurement of antithrombin III-heparin cofactor and alpha2 macroglobulin in disseminated intravascular coagulation and hepatic failure coagulopathy.

The inhibition of human plasma kallikrein by antithrombin III.

The role of heparin in the thrombin-antithrombin III reaction.

3H-heparin and antithrombin III in the isolated liver perfusion.

Heparin-antithrombin III binding. In vitro and in vivo studies.

Venous thrombosis, heparin-induced antithrombin III deficiency, and factor VIII.

Suggest Documents

Antithrombin-III assay without influence of heparin cofactor II.

Simultaneous determination of plasma prothrombin and antithrombin III (heparin cofactor).

Laboratory diagnosis of antithrombin and heparin cofactor II deficiency.

Inhibition of purified plasma kallikrein by antithrombin III and heparin.

The inhibition of thrombin and chymotrypsin by heparin-cofactor II.

Metabolism of antithrombin III (heparin cofactor) in man: effects of venous thrombosis and of heparin administration.

Heparin cofactor II deficiency in the elderly: comparison with antithrombin III.

Different glycoforms of human thrombomodulin. Their glycosaminoglycan-dependent modulatory effects on thrombin inactivation by heparin cofactor II and antithrombin III.

Antithrombin III and heparin.

Antithrombin III and heparin.

A new two-stage functional assay for antithrombin-III (heparin cofactor): clinical and laboratory evaluation.

Antithrombin-heparin cofactor: an inhibitor of plasma kallikrein.

Effect of heparin modification on its activity in enhancing the inhibition of thrombin by antithrombin III.

Evidence for a plasma inhibitor of the heparin accelerated inhibition of factor Xa by antithrombin III.

Effect of heparin on thrombin inactivation by antithrombin-III.

Interaction of factor Xa with heparin does not contribute to the inhibition of factor Xa by antithrombin III-heparin.

Letter: DIC-fibrinolysis with low antithrombin-heparin cofactor.

Heparin-induced decrease in circulating antithrombin-III.

Immunologic measurement of antithrombin III-heparin cofactor and alpha2 macroglobulin in disseminated intravascular coagulation and hepatic failure coagulopathy.

The inhibition of human plasma kallikrein by antithrombin III.

The role of heparin in the thrombin-antithrombin III reaction.

3H-heparin and antithrombin III in the isolated liver perfusion.

Heparin-antithrombin III binding. In vitro and in vivo studies.

Venous thrombosis, heparin-induced antithrombin III deficiency, and factor VIII.

Mechanism of potentiation of antithrombin III and heparin cofactor II inhibition by sulfated xylans.

Recommend Documents

Follow Us